Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Tesamorelin Alternative to Egrifta SV: Formulation Comparison

Egrifta SV (Brand) ≥98% (FDA-approved batch testing) $4,800–$6,200 No (pre-filled pen) Yes (FDA-mandated per batch) Most expensive option with insurance coverage advantage. Identical peptide to compounded versions but 5× the cost without coverage 503B Compound

This comparison does not assign a generated winner or score.

  • Egrifta SV (Brand)
  • ≥98% (FDA-approved batch testing)
  • $4,800–$6,200
  • No (pre-filled pen)
  • Yes (FDA-mandated per batch)
  • Most expensive option with insurance coverage advantage. Identical peptide to compounded versions but 5× the cost without coverage
  • 503B Compounded Tesamorelin
  • ≥98% (USP <797> sterile prep + independent COA)
  • $800–$1,200
  • Yes (bacteriostatic water)
  • Yes (LAL endotoxin + sterility per USP)
  • Best cost-to-purity ratio. Same peptide, same standards, 60–80% cost reduction; requires reconstitution competency
  • Research-Grade Lyophilized Tesamorelin
  • ≥97% (HPLC verified, COA provided)
  • $600–$900
  • Yes (sterile water or bacteriostatic)
  • Optional (COA shows peptide purity, not sterility per batch)
  • Lowest cost but demands cold-chain discipline and sterile technique. Ideal for high-volume research protocols with lab infrastructure
  • The bottom line: peptide purity above 98% ensures consistent GHRH receptor binding regardless of formulation. Egrifta SV charges for FDA approval and convenience. Compounded versions charge for the peptide and sterile preparation. Research-grade versions charge for the raw peptide. The molecular structure and pharmacological mechanism don't change across these categories. Cost, reconstitution requirements, and regulatory classification do.